REGENXBIO RGNX 深 沪
交易中 09-20 11:22:42 美东时间
11.95
-0.550
-4.40%
华盛通- 最 高12.47
- 今 开12.37
- 成交量 18.45万股
- 最 低 11.91
- 昨 收 12.50
- 总市值 5.26亿
- 52周最高 28.80
- 市盈率 静 --
- 换手率 0.42%
- 52周最低 10.49
- 委 比 98.28%
- 总股本 4399.20万
- 历史最高 85.10
- 量 比 1.27
- 振 幅 4.48%
- 历史最低 7.07
- 每 手 1
- 风险率 3.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RegenXBio Appoints New EVP and CFO Amidst Key Developments
RegenXBio ( ($RGNX) ) has shared an update. Mitchell Chan has been appointed as...
09-18 05:28
REGENXBIO names Mitchell Chan as finance chief
REGENXBIO (NASDAQ:RGNX) said it has appointed Mitchell Chan as its CFO, and executive vice president. Chan has nearly 20 years of experience, and most recently served as the operating partner at Catal...
09-17 19:18
REGENXBIO Names Mitchell Chan As Executive Vice President And CFO, Effective Today
Chan succeeds Vit Vasista, who served as Executive Vice President and Chief Financial Officer since 2009. Mr. Vasista will serve as an advisor to the Company through January 3, 2025, to support a smooth
09-17 19:12
Dyne stock tumbles 31% amid drug updates, management changes
Shares of Dyne Therapeutics (NASDAQ:DYN) fell 31% Tuesday after the company released new data from a clinical trial called DELIVER for its drug DYNE-251 in the treatment of Duchenne muscular dystrophy...
09-04 04:48
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global...
08-30 04:05
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) toda...
08-08 19:05
Regenxbio Q2 2024 GAAP EPS $(1.05) Beats $(1.29) Estimate, Sales $22.295M Miss $22.973M Estimate
Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(1.29) by 18.6 percent. This is a 36.75 percent increase over losses of $(1.66) per share from the same
08-02 04:24
Sanofi unit Genzyme sues Sarepta alleging patent infringement in Duchenne drug
Sanofi (NASDAQ:SNY)-owned Genzyme has sued Sarepta Therapeutics (NASDAQ:SRPT) accusing the latter's Duchenne muscular dystrophy therapy Elevidys of violating two of its patents. The patents in questio...
08-01 03:06
PepGen stock tumbles 25% following release of DMD drug data
PepGen (NASDAQ:PEPG) stock plunged 25% in post-market trading Tuesday after the company released data for its drug PGN-EDO51 in the treatment of Duchenne muscular dystrophy, or DMD. PepGen reported da...
07-31 07:37
Analysts’ Top Healthcare Picks: KalVista Pharmaceuticals (KALV), RegenXBio (RGNX)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
07-29 19:50
